Ariana Pelosci is an editor at Cancer Network.
First-line Niraparib Improves PFS in Ovarian Cancer
May 18th 2022An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,
PFS Prolonged With Continuous Enzalutamide After AR Inhibitor Progression in mCRPC
February 18th 2022According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
In Older Patients With Chronic Lymphocytic Leukemia Ibrutinib Regimens Yield Superior Efficacy
December 13th 2021Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.
Outcomes in Early Hormone Receptor-Positive or- Negative Breast Cancer Not Improved with Metformin
December 7th 2021Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.